Albumin fusion proteins
AssigneeHuman Genome Sciences, Inc.
InventorsCraig A. Rosen, Steven M. Ruben, Olivier Blondel
Life of this patent
Estimating the term…
Abstract
Provided herein are albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins and vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins and using these nucleic acids, vectors, and/or host cells also are provided. Further described are pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Claims21
An albumin fusion protein comprising an insulin polypeptide fused to albumin, wherein the fusion protein has insulin activity, and wherein:
- (a) the insulin polypeptide is selected from a wild-type insulin, an insulin fragment, and an insulin variant, and (b) the albumin is selected from a wild-type albumin, an albumin fragment, and an albumin variant, wherein the albumin increases the serum plasma half-life of the insulin polypeptide.
A method of treating, preventing, diagnosing or ameliorating a disease, disorder or condition in a subject in need thereof comprising administering an effective amount of an albumin fusion protein comprising an insulin polypeptide fused to albumin, wherein the fusion protein has insulin activity, and wherein:
- (a) the insulin polypeptide is selected from a wild-type insulin, an insulin fragment, and an insulin variant, and (b) the albumin is selected from a wild-type albumin, an albumin fragment, and an albumin variant, wherein the albumin increases the serum plasma half-life of the insulin polypeptide.
Dependencies are inferred from the claim text.